Retatrutide vs Tirzepatide vs Semaglutide

Three names dominate conversations about metabolic research peptides: semaglutide, tirzepatide, and retatrutide. They are often lumped together, but they represent three distinct generations of design, each adding another receptor to the mix. The clearest way to understand them is to line them up by the number of pathways each one activates.

One, two, three: the agonist ladder

The simplest mental model is to count receptor targets. Semaglutide hits one, tirzepatide hits two, and retatrutide hits three. Each step up the ladder adds a mechanism and, with it, a new set of research questions.

Semaglutide: the single-agonist benchmark

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It activates a single pathway associated with glucose regulation and appetite signalling, and it is engineered for a long half-life. Because it is the most studied member of this family, it functions as the reference standard that newer, more complex compounds are measured against.

Tirzepatide: adding the GIP arm

Tirzepatide is a dual agonist. Alongside GLP-1, it also engages the glucose-dependent insulinotropic polypeptide (GIP) receptor. Adding GIP activity to GLP-1 is the defining feature of the dual-agonist concept, and it made tirzepatide the natural next step in the literature after single-agonist work matured. Researchers use it when the question involves how two incretin pathways behave together rather than in isolation.

Retatrutide: the triple agonist

Retatrutide extends the design one receptor further, adding glucagon receptor activity to GLP-1 and GIP. That glucagon arm is the distinguishing element, since it is associated in research models with energy expenditure and hepatic metabolism rather than insulin signalling alone. As the newest of the three, retatrutide has the smallest published record, but it represents the current frontier of multi-agonist design.

Which one fits which study

• Semaglutide is the choice when you need a well-documented single-pathway GLP-1 baseline to anchor a comparison.
• Tirzepatide suits work focused on combined GIP and GLP-1 signalling and how a dual agonist differs from a single one.
• Retatrutide is for research centred on full triple-receptor activity and the added glucagon dimension.

Many research programs use more than one of these compounds precisely because they form a ladder. Running a single, dual, and triple agonist side by side lets a team isolate what each additional receptor contributes.

Consistency across the set

Comparing three compounds only works if each one is what the label says and behaves the same from lot to lot. Peptides are sensitive to heat, light, and handling, so identity and purity are not details, they are the whole basis of a valid comparison. Every LYFE Science compound is verified by HPLC and mass spectrometry, with a certificate of analysis available for the lot you receive, so your baseline stays stable across an entire study.

Ordering in Canada

LYFE Science is a Canadian supplier shipping nationwide by Canada Post. Shipping is a flat $25 and free over $150, sent in neutral packaging, with same-day dispatch on orders paid before noon ET and delivery typically within one to three business days across most of the country. Pay by Interac e-Transfer or crypto (BTC, ETH, SOL, USDC, USDT). New to the incretin class? Start with our peptide guide, then browse what is in stock.

Semaglutide, tirzepatide, and retatrutide are best understood as three rungs on the same ladder: one pathway, two, then three. Pick the rung that matches your research question and source each compound from a supplier that documents every lot.

Buy research peptides in Canada